Wilson L D, Henning R J, Suttheimer C, Lavins E, Balraj E, Earl S
Department of Emergency Medicine, Mt. Sinai Medical Center Cleveland, Ohio 44106, USA.
J Cardiovasc Pharmacol. 1995 Dec;26(6):965-73. doi: 10.1097/00005344-199512000-00017.
Twelve million Americans abuse both cocaine and ethanol each year because this drug combination produces a pronounced and prolonged euphoria. However, these substances in combination are substantially more toxic than either drug alone. This toxicity may be due to cocaethylene, which has been detected in the serum of patients who have used cocaine and ethanol and two require emergency treatment. Cocaethylene is a pharmacologically active cocaine metabolite formed in the liver only in the presence of ethanol. To investigate the cardiovascular effects of cocaethylene, we randomized 15 mongrel dogs to receive 11.25 mg/kg (n = 4), 7.5 mg/kg (n = 6), or 3.75 mg/kg (n = 5) of cocaethylene as an intravenous (i.v.) bolus. These doses were chosen to achieve serum concentrations of cocaethylene consistent with those observed in patients with cocaine and ethanol toxicity. The ECG and the femoral arterial, left ventricular (LV), and pulmonary artery pressure were measured continuously, and cardiac output (CO) and serum levels of cocaethylene were monitored at specific intervals before and after drug administration. The maximal rate of increase and decrease in LV pressure (LVP), i.e., (dP/dt)max and (dP/dt)min, were determined as our indexes of ventricular contractility and relaxation. Cocaethylene concentrations peaked 2-4 min after each bolus and then decreased in a curvilinear manner. Cocaethylene's half-life (t1/2) was 150 +/- 15.1 min (mean +/- SEM). The greatest hemodynamic changes occurred at the peak cocaethylene serum concentrations in each group. In comparison with control measurements, cocaethylene in concentrations of 11.25 and 7.5 mg/kg decreased (dP/dt)max by 81 and 43% and decreased (dP/dt)min by 80 and 36%, respectively. In these two groups, cocaethylene decreased stroke volume (SV) by 29 and 33% and reduced mean arterial pressure (MAP) by 65 and 30%, respectively. Cocaethylene increased pulmonary artery wedge pressure (PAWP) by 70 and 67% in the 11.25- and 7.5-mg/kg groups. These hemodynamic changes persisted for 60 min after the bolus administration. In each of the three groups, cocaethylene increased the QRS interval duration by 60, 32, and 44% and the QTc interval by 38, 21, and 17%. These ECG changes persisted for 120 min. These experiments suggest cocaethylene depresses the myocardium. Cocaethylene may be a major contributor to the delayed but substantial cardiotoxicity that occurs in individuals who use both cocaine and ethanol.
每年有1200万美国人同时滥用可卡因和乙醇,因为这种药物组合会产生显著且持久的欣快感。然而,这两种物质混合使用时的毒性比单独使用任何一种药物都要大得多。这种毒性可能归因于可卡乙碱,在同时使用可卡因和乙醇的患者血清中已检测到可卡乙碱,有两人需要紧急治疗。可卡乙碱是一种仅在有乙醇存在时于肝脏中形成的具有药理活性的可卡因代谢物。为了研究可卡乙碱对心血管的影响,我们将15只杂种狗随机分为三组,分别静脉推注11.25毫克/千克(n = 4)、7.5毫克/千克(n = 6)或3.75毫克/千克(n = 5)的可卡乙碱。选择这些剂量是为了使可卡乙碱的血清浓度与可卡因和乙醇中毒患者中观察到的浓度一致。连续测量心电图、股动脉、左心室(LV)和肺动脉压力,并在给药前后的特定时间间隔监测心输出量(CO)和可卡乙碱的血清水平。左心室压力(LVP)的最大上升和下降速率,即(dP/dt)max和(dP/dt)min,被确定为我们评估心室收缩性和舒张性的指标。每次推注后可卡乙碱浓度在2 - 4分钟达到峰值,然后呈曲线下降。可卡乙碱的半衰期(t1/2)为150 +/- 15.1分钟(平均值 +/- 标准误)。每组中最大的血流动力学变化发生在可卡乙碱血清浓度峰值时。与对照测量相比,浓度为11.25和7.5毫克/千克的可卡乙碱使(dP/dt)max分别降低了81%和43%,使(dP/dt)min分别降低了80%和36%。在这两组中,可卡乙碱使每搏输出量(SV)分别降低了29%和33%,使平均动脉压(MAP)分别降低了65%和30%。在11.25毫克/千克和7.5毫克/千克组中,可卡乙碱使肺动脉楔压(PAWP)分别升高了70%和67%。这些血流动力学变化在推注给药后持续60分钟。在三组中的每一组中,可卡乙碱使QRS间期持续时间分别增加了60%、32%和44%,使QTc间期分别增加了38%、21%和17%。这些心电图变化持续120分钟。这些实验表明可卡乙碱会抑制心肌。可卡乙碱可能是导致同时使用可卡因和乙醇的个体出现延迟但严重的心脏毒性的主要因素。